李嘉诚卖掉中药板块后,和黄医药会更好吗?

健识局
20 Mar

3月19日晚,和黄医药发布2024年年报:去年实现收入6.3亿美元,同比下滑24.8%,净利润为3770万美元,低于2023年的1亿美元。和黄医药的瘦身计划会贯穿2025年,可能会持续影响公司的业绩。2024年底,和黄医药宣布:卖掉上海和黄药业45%的股权,手中只保留5%。李嘉诚从20多年前开始就陆续布局中药业务,分别和同仁堂、白云山、上海医药三大国企联营,如今已基本悉数卖尽。上海和黄医药2024...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10